Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Basiliximab Clear all
Terminated Phase 2 Interventional

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

NCT00023244
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Basiliximab, Cyclosporine, Tacrolimus, Sirolimus, Methylprednisolone, Prednisone, Bactrim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 20 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 4 Interventional

Reference Group Trial for The ONE Study

NCT01656135
View directory record Official record
Conditions
End-stage Renal Failure, Kidney Graft Rejection
Interventions
Blood drawing for immune monitoring and questionnaires
Other
Lead sponsor
University of Regensburg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation

NCT02123108
View directory record Official record
Conditions
Liver Transplantation
Interventions
Basiliximab, Tacrolimus, Mycophenolic Acid
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients

NCT00229138
View directory record Official record
Conditions
Kidney Transplantation
Interventions
EC-MPS, Tacrolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
291 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

NCT00975975
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis, Anemia, Aplastic, Hemoglobinuria, Paroxysmal
Interventions
Basiliximab
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 2, 2026, 5:42 PM EDT
Completed No phase listed Observational

Induction Related BK Viremia in Renal Transplant Patients

NCT00610961
View directory record Official record
Conditions
Disease Due to BK Polyomavirus, Transplantation Infection, Disorder Related to Transplantation
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

NCT00235300
View directory record Official record
Conditions
Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
Interventions
Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab)
Biological · Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

Efficacy of Islet After Kidney Transplantation

NCT00468117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

NCT00113269
View directory record Official record
Conditions
Kidney Transplantation
Interventions
basiliximab, rabbit anti-thymocyte globulin, tacrolimus, alemtuzumab, mycophenolate mofetil, steroids
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Sep 2, 2026, 5:42 PM EDT
Terminated Phase 3 Interventional Results available

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

NCT02411084
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Begelomab, Conventional Second-line Treatment
Biological
Lead sponsor
Adienne SA
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Duarte, California • Westwood, Kansas • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia

NCT00626483
View directory record Official record
Conditions
Malignant Neoplasms Brain
Interventions
RNA-loaded dendritic cell vaccine, basiliximab
Biological · Drug
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Sep 2, 2026, 5:42 PM EDT
Withdrawn Not applicable Interventional

Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients

NCT01033500
View directory record Official record
Conditions
Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Kidney Transplantation
Interventions
Belatacept
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

NCT02342782
View directory record Official record
Conditions
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions
Yttrium Y 90 Basiliximab, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 2, 2026, 5:42 PM EDT
Terminated Not applicable Interventional

Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations

NCT01387659
View directory record Official record
Conditions
Diabetes, Immunosuppression
Interventions
Gastric emptying test
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

NCT02464878
View directory record Official record
Conditions
Kidney Transplant, Type 1 Diabetes
Interventions
Alpha 1-Antitrypsin, Islet Transplantation, Thymoglobulin, Basiliximab, Etanercept
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 2, 2026, 5:42 PM EDT
Active, not recruiting Phase 1 Interventional

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT05139004
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate, Indium In 111-DOTA-Basiliximab, Melphalan, Palifermin, Total Lymphoid Irradiation, Total Marrow Irradiation, Yttrium Y 90 Basiliximab
Procedure · Biological · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
60 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

NCT01842139
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions
basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG, poly ICLC, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

Freedom Study: Myfortic in Kidney Transplant Patients

NCT00101738
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Myfortic
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
9
States / cities
San Francisco, California • Tampa, Florida • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2011 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 3 Interventional

Islet Transplantation in Type 1 Diabetes

NCT00434811
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus, Tacrolimus, Etanercept, Islet Transplantation, Basiliximab
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 2, 2026, 5:42 PM EDT
Terminated Phase 2 Interventional

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

NCT00646425
View directory record Official record
Conditions
Non-infectious Uveitis
Interventions
Basiliximab, Placebo
Drug
Lead sponsor
Cerimon Pharmaceuticals
Industry
Eligibility
12 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Cambridge, Massachusetts • Kansas City, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 2, 2026, 5:42 PM EDT
No Longer Available No phase listed Expanded access

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

NCT01049633
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 2 Interventional

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Sep 2, 2026, 5:42 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

NCT02921789
View directory record Official record
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions
Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 2, 2026, 5:42 PM EDT